Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 18 years of age;~* Evidence of at least one donor-specific antibody (DSA);~* Recipient of a kidney transplant;~* Achieved a steady-state, post-transplant eGFR ≥ 40 mL/min/1.73 m2 within 60 days of post-transplant OR a 50% increase in urine output with a 50% decrease in serum creatinine over the first 7 days post-transplant in subjects with slow or delayed graft function;~* Acute AMR.~Exclusion Criteria:~* Recipient of an en bloc kidney transplant;~* Current active hepatitis C virus (HCV) infection;~* Active bacterial or fungal infection;~* Ongoing dialysis \>2 weeks;~* Known congenital bleeding or coagulopathy disorder;~* Current cancer or a history of cancer;~* Female subjects who are pregnant or breast feeding;~* Male or female subjects who are unwilling to use contraception or who are not surgically sterile.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C1-INH (Type: EXPERIMENTAL): C1-esterase inhibitor
- Placebo (Type: PLACEBO_COMPARATOR): Excipients of C1-INH plus albumin

Based on this trial design, predict the completion outcome and termination type (if applicable).